Skip to content
Epoprostenol
Flolan, Veletri (epoprostenol) is a small molecule pharmaceutical. Epoprostenol was first approved as Flolan on 1995-09-20. It is used to treat arteriosclerosis, peripheral vascular diseases, pulmonary hypertension, purpura, and respiratory distress syndrome amongst others in the USA. The pharmaceutical is active against prostaglandin E2 receptor EP1 subtype. In addition, it is known to target prostaglandin E2 receptor EP4 subtype and prostacyclin receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Flolan, Veletri (generic drugs available since 2008-04-23)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Epoprostenol sodium
Tradename
Company
Number
Date
Products
VELETRIActelionN-022260 RX2008-06-27
2 products, RLD, RS
FLOLANGSKN-020444 RX1995-09-20
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
diluent flolanNew Drug Application2019-11-15
veletriNew Drug Application2021-01-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
arteriosclerosisEFO_0009086D001161I70
peripheral vascular diseasesEFO_0003875D016491I73.9
pulmonary hypertensionEFO_0001361D006976I27.20
purpuraHP_0000979D011693D69.2
respiratory distress syndromeEFO_1000637D012128J80
systemic sclerodermaEFO_0000717D012595M34
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Epoprostenol Sodium, Veletri, Actelion
83188022027-03-15DP
85982272027-02-02
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC09: Epoprostenol
HCPCS
Code
Description
J1325
Injection, epoprostenol, 0.5 mg
K0455
Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol)
S0155
Sterile dilutant for epoprostenol, 50 ml
S9347
Home infusion therapy, uninterrupted, long-term, controlled rate intravenous or subcutaneous infusion therapy (e.g., epoprostenol); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
Clinical
Clinical Trials
371 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501487831116197
Liver neoplasmsD008113EFO_1001513C22.04661316
Large b-cell lymphoma diffuseD016403C83.3—44119
Wilms tumorD009396———1—1
CarcinomaD002277C80.0———1—1
Circulating neoplastic cellsD009360———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C1651910—231
Triple negative breast neoplasmsD0647264189—127
Esophageal neoplasmsD004938C15494—114
AdenocarcinomaD000230153—18
SarcomaD012509233——7
Inflammatory breast neoplasmsD058922123——6
Urinary bladder neoplasmsD001749C67—22—26
Pancreatic neoplasmsD010190EFO_0003860C25—41—15
Neoadjuvant therapyD020360—52——5
LymphomaD008223C85.9—31——4
Show 18 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8094———10
Prostatic neoplasmsD011471C6111———2
NeutropeniaD009503D7011———2
Germ cell and embryonal neoplasmsD009373—2———2
Hepatocellular carcinomaD006528C22.011——12
Lobular carcinomaD018275EFO_0000570—1———1
Invasive hydatidiform moleD002820D39.2—1———1
Head and neck neoplasmsD00625811———1
Febrile neutropeniaD064147—1———1
Healthy volunteers/patients——1———1
Show 13 more
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179————11
Biliary tract neoplasmsD001661C24.9————11
LeiomyosarcomaD007890————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEPOPROSTENOL
INNepoprostenol
Description
Prostaglandin I2 is a prostaglandins I. It has a role as a mouse metabolite. It is a conjugate acid of a prostaglandin I2(1-).
Classification
Small molecule
Drug classprostaglandins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21
Identifiers
PDB—
CAS-ID35121-78-9
RxCUI8814
ChEMBL IDCHEMBL1139
ChEBI ID15552
PubChem CID5282411
DrugBankDB01240
UNII IDDCR9Z582X0 (ChemIDplus, GSRS)
Target
Agency Approved
PTGER1
PTGER1
Organism
Homo sapiens
Gene name
PTGER1
Gene synonyms
NCBI Gene ID
5731
Protein name
prostaglandin E2 receptor EP1 subtype
Protein synonyms
PGE receptor, EP1 subtype, PGE2 receptor EP1 subtype, prostaglandin E receptor 1 (subtype EP1), 42kD, prostaglandin E receptor 1 (subtype EP1), 42kDa, prostaglandin E receptor 1, subtype EP1, Prostanoid EP1 receptor
Uniprot ID
Q8NHB2
Mouse ortholog
Ptger1 (19216)
prostaglandin E2 receptor EP1 subtype (P35375)
Alternate
PTGER4
PTGER4
PTGIR
PTGIR
Organism
Homo sapiens
Gene name
PTGER4
Gene synonyms
PTGER2
NCBI Gene ID
5734
Protein name
prostaglandin E2 receptor EP4 subtype
Protein synonyms
PGE receptor, EP4 subtype, PGE2 receptor EP4 subtype, prostaglandin E receptor 4 (subtype EP4), Prostanoid EP4 receptor
Uniprot ID
Q3MJ87
Mouse ortholog
Ptger4 (19219)
prostaglandin E2 receptor EP4 subtype (P32240)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,791 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15,343 adverse events reported
View more details